Preparation and Administration:

• Fabrazyme is supplied as a powder and must be reconstituted and diluted before use.
  
  
• The medication is prepared by a trained healthcare professional under sterile conditions.
  
  
• Administered as an intravenous infusion, typically over 120 minutes.
  
  
• Infusions are usually done in a hospital or infusion center, though home infusion may be an option for stable patients.
  
  

Steps During Treatment:

• Vitals are monitored before, during, and after the infusion to detect any adverse reactions.
  
  
• If a patient experiences infusion reactions (fever, chills, rash, or difficulty breathing), the infusion rate may be slowed or temporarily stopped.
  
  

Post-Infusion Care:

• Patients are observed for at least 30–60 minutes after the infusion.
  
  

Any unusual symptoms should be reported immediately to the healthcare team.

Fabrazyme works by replacing the missing or deficient alpha-galactosidase A enzyme in individuals with Fabry disease. In healthy individuals, this enzyme breaks down GL-3, preventing it from accumulating inside cells. People with Fabry disease lack this enzyme, leading to a progressive buildup of GL-3 in various tissues.

Agalsidase beta, the active ingredient in Fabrazyme, is designed to mimic the body’s natural enzyme. After intravenous infusion, it enters the bloodstream and is absorbed by cells. Once inside the lysosomes (the cell’s recycling centers), Fabrazyme breaks down the excess GL-3.

Key benefits of this mechanism include:

• Reducing GL-3 deposits in blood vessels and organs.
  
  
• Improving organ function, especially in the kidneys and heart.
  
  
• Alleviating symptoms like pain, fatigue, and gastrointestinal issues.
  
  
• Slowing the progression of the disease.
  
  

Early and consistent treatment with Fabrazyme can significantly improve long-term outcomes for individuals with Fabry disease.

Common Side Effects:

• Infusion-related reactions:
  
  
  • Chills
    
    
  • Fever
    
    
  • Headache
    
    
  • Nausea
    
    
  • Fatigue
    
    
• Pain in muscles or joints
  
  
• Abdominal discomfort or diarrhea
  
  
• Skin rash or itching
  
  

These are usually mild to moderate and can often be managed with pre-medication or slowing the infusion rate.

Serious Side Effects:

• Anaphylaxis: A severe allergic reaction that may involve swelling, breathing difficulty, and a drop in blood pressure. Requires immediate emergency treatment.
  
  
• Antibody development: Some patients may develop antibodies to agalsidase beta, which could reduce the drug’s effectiveness or increase side effects.
  
  
• Lung complications: Rare but possible, particularly in patients with underlying respiratory conditions.
  
  

Monitoring and early intervention help manage these risks effectively.

• Hypersensitivity Reactions: Fabrazyme may cause allergic reactions during or after the infusion. Facilities must be equipped for emergency management.
  
  
• Antibody Formation: Patients may develop neutralizing antibodies, especially during the early months of treatment. Blood tests may be conducted to monitor immune response.
  
  
• Pregnancy and Breastfeeding:
  
  
  • Use in pregnancy should be considered only if clearly needed.
    
    
  • It is unknown whether Fabrazyme passes into breast milk; breastfeeding should be discussed with a doctor.
    
    
• Renal or Cardiac Conditions: Patients with advanced kidney disease or cardiac complications require careful monitoring during treatment.
  
  

Pediatric Use: Approved for use in children as young as 8 years old; dosing is adjusted based on weight and tolerance.

Fabrazyme does not typically interact with most oral medications, but caution is still needed. Important considerations include:

• Immunosuppressants: May interfere with the body’s immune response to Fabrazyme and increase the risk of side effects.
  
  
• Vaccinations: Use of Fabrazyme does not interfere directly with vaccines, but patients on immunosuppressants may require special vaccination schedules.
  
  
• Other enzyme therapies: Using multiple biologics or ERTs may require careful monitoring to avoid immune system complications.
  
  

Patients should inform their healthcare provider about all medications, supplements, and herbal products they are taking.

• Standard Dose: 1 mg/kg of body weight every two weeks by IV infusion.
  
  
• Dose Adjustments: Typically not necessary but may be altered in the event of severe reactions or antibody formation.
  
  
• Missed Doses: If a dose is missed, it should be administered as soon as possible. The regular schedule may resume from the new infusion date.
  
  
• Monitoring: Regular tests may include:
  
  
  • Kidney function tests
    
    
  • Heart imaging
    
    
  • GL-3 levels
    
    
  • Immune response monitoring
    
    

Dose modifications or supportive care measures may be recommended based on these results.

Fabrazyme is a specialty prescription medication and requires:

• Diagnosis Confirmation: Patients must have a confirmed diagnosis of Fabry disease, usually through enzyme testing or genetic screening.
  
  
• Ongoing Monitoring: Physicians must track response and tolerance through regular lab and clinical assessments.
  
  
• Infusion Facility Access: Due to the IV nature of the treatment, administration must be supervised by qualified professionals.
  
  

Insurance coverage is often available, though prior authorization may be required. Manufacturer support programs may also assist with cost or logistics for eligible patients.

• What is Fabrazyme used for?
  It is prescribed to treat Fabry disease, a rare genetic disorder caused by a deficiency of the enzyme alpha-galactosidase A.

• What is the active ingredient?
  Agalsidase beta, a recombinant form of the missing human enzyme.

• How does Fabrazyme work?
  It replaces the deficient enzyme, helping break down globotriaosylceramide (GL-3) and reduce its buildup in cells.

• Does Fabrazyme cure Fabry disease?
  No, it does not cure the disease but helps manage symptoms and slow progression.

• How is Fabrazyme given?
  By intravenous (IV) infusion every two weeks under medical supervision.

• How long is each infusion?
  Usually lasts 1.5 to 2 hours, but may be adjusted for patient tolerance.

• What are the common side effects?
  Fever, chills, headache, nausea, fatigue, flushing, itching, and infusion-site reactions.

• Are there serious side effects?
  Yes, including severe allergic reactions, anaphylaxis, breathing problems, and chest pain during infusion.

• Can infusion reactions occur?
  Yes, infusion reactions are common and may require antihistamines, corticosteroids, or slowing the infusion rate.

• Who should not take Fabrazyme?
  People with severe allergic reactions to agalsidase beta or any ingredient.

• Is Fabrazyme used in children?
  Yes, approved for pediatric patients as young as 2 years old.

• Is Fabrazyme safe during pregnancy?
  Limited data—should be used only if the benefits outweigh the risks.

• Can I use Fabrazyme while breastfeeding?
  It is not known if it passes into breast milk—consult a doctor before use.

• Does Fabrazyme improve kidney or heart function?
  It may help slow kidney damage, reduce heart enlargement, and improve pain and quality of life in Fabry disease patients.

• How long do patients need Fabrazyme treatment?
  It is generally a lifelong therapy for Fabry disease.

• Do patients need monitoring while on Fabrazyme?
  Yes, monitoring includes kidney function, heart function, antibody development, and infusion tolerance.

• Is Fabrazyme the only treatment for Fabry disease?
  No, other options include Galafold (migalastat, for amenable mutations) and supportive therapies.

• Is there a generic version of Fabrazyme?
  Not a generic, but a biosimilar (agalsidase beta products) may be available in some regions.

• Where is Fabrazyme available?
  At specialty pharmacies and infusion centers with a prescription.